GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK plc GSK announced that it has signed an ... on the remaining three — Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

Those are just a few of the classic storylines Lifetime movie fans expect to see when they switch on the TV, and, this summer, GSK is adding another real-life danger to Lifetime's lineup ...

You can reach Andrew on Signal at drewqjoseph.45. LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront ...

GSK GSK1.80%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

GSK has carried pipeline momentum into Q1, with two new U.S. approvals as highlighted. Looking ahead, we expect three more approvals for Nucala COPD, Blenrep and depemokimab this year, with PDUFA ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...